Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy

To the Editor Hernandez and colleagues estimated the total cost of chimeric antigen receptor T-cell (CAR-T) immunotherapy by presenting 11 patient-treatment pathways based on receipt of CAR-T infusion, development of cytokine release syndrome, and response to treatment. We agree that the treatment acquisition costs of tisagenlecleucel (Kymriah; Novartis) ($475 000 for pediatric leukemia) and axicabtagene ciloleucel (Yescarta; Kite Pharma) ($373 000 for adult lymphoma) are not an accurate representation of the total cost of CAR-T immunotherapy.

https://ift.tt/2EeFCIY